美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

新桥生物

2.00

+0.09004.71%

盘后：2.010.0100+0.50%19:46 EDT

成交量：44.30万

成交额：87.59万

市值：2.31亿

市盈率：-4.14

高：2.02

开：1.91

低：1.89

收：1.91

52周最高：6.79

52周最低：1.46

股本：1.15亿

流通股本：6,421.29万

量比：1.46

换手率：0.69%

股息：- -

股息率：- -

每股收益(TTM):-0.4830

每股收益(LYR):-0.9225

净资产收益率：-59.10%

总资产收益率：-34.98%

市净率：1.15

市盈率(LYR):-2.17

数据加载中...

总览公司新闻资讯公告

新桥生物公布2026年上半年财务业绩，展示管线进展与战略执行亮点

新桥生物发布2026年上半年财务业绩，彰显管线动能与战略执行力

新桥生物将于2026年8月20日（周四）披露2026年上半年财务业绩并发布公司最新动态

新桥生物任命Srishti Gupta博士为首席执行官

BUZZ——美国股市动态-安科科技、Dynatrace、Corvex

新桥生物Givastomig获美国FDA快速通道认定，用于HER2阴性转移性胃癌一线治疗

市场快讯——美股行情动态-高通、Robinhood、Mobileye

热门话题-NovaBridge股价上涨，因其胃癌联合用药获FDA快速通道资格

新桥生物旗下Givastomig的注册性三期临床试验最早有望于2026年第四季度启动

新桥生物Givastomig获FDA快速通道资格，用于一线治疗HER2阴性转移性胃癌

新桥生物：预计最早于2026年第四季度启动注册性三期联合试验

新桥生物：FDA确认Givastomig有望符合加速审批资格

新桥生物计划于2026年第四季度启动以客观缓解率为主要终点的注册性三期联合试验

新桥生物宣布与FDA就胃腺癌药物Givastomig加速审批路径达成建设性B类会议

BUZZ--美国股票走势-Hims & Hers、Live Nation、NovaBridge

BUZZ-NovaBridge 股价上涨，因眼病药物中期试验显现前景

新桥生物公布二期a阶段顶线数据：Vis-101为湿性年龄相关性黄斑变性提供快速、强劲且持久的治疗反应

新桥生物Vis-101试验结果亮眼：平均BCVA改善超10个ETDRS字母，中位CST降低100-150微米

中东欧市场：波兰央行下调基准利率后，兹罗提保持涨势

环球市场播报

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/NBP/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"新桥生物","latestPrice":2,"timestamp":1787342400000,"preClose":1.91,"halted":0,"volume":443031,"hourTrading":{"tag":"盘后","latestPrice":2.01,"preClose":2,"latestTime":"19:46 EDT","volume":877,"amount":1748.9,"timestamp":1787356001071,"change":0.01,"changeRate":0.005,"amplitude":0.01},"delay":0,"changeRate":0.04712041884816758,"floatShares":64212900,"shares":115266053,"eps":-0.483,"marketStatus":"休市中","change":0.09,"latestTime":"08-21 16:00:00 EDT","open":1.91,"high":2.02,"low":1.889,"amount":875899.8435281999,"amplitude":0.068586,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.483,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":1.91,"preHourTrading":{"tag":"盘前","latestPrice":1.95,"preClose":1.91,"latestTime":"09:15 EDT","volume":4169,"amount":7804.1324515,"timestamp":1787318100261,"change":0.04,"changeRate":0.020942,"amplitude":0.041885},"postHourTrading":{"tag":"盘后","latestPrice":2.01,"preClose":2,"latestTime":"19:46 EDT","volume":877,"amount":1748.9,"timestamp":1787356001071,"change":0.01,"changeRate":0.005,"amplitude":0.01},"volumeRatio":1.4636051748026337,"impliedVol":1.8929,"impliedVolPercentile":0.7635},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","floatShares":64212900,"roa":"-34.98%","roe":"-59.10%","lyrEps":-0.922468,"volumeRatio":1.4636051748026337,"shares":115266053,"dividePrice":0,"high":2.02,"amplitude":0.068586,"preClose":1.91,"low":1.889,"week52Low":1.46,"pbRate":"1.15","week52High":6.79,"institutionHeld":0,"latestPrice":2,"eps":-0.483,"divideRate":0,"volume":443031,"delay":0,"ttmEps":-0.483,"open":1.91,"prevYearClose":3.98,"prevWeekClose":1.96,"prevMonthClose":1.6,"prevQuarterClose":1.95,"fiveDayClose":1.96,"twentyDayClose":1.77,"sixtyDayClose":1.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBP\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"NBP","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787212800000,"name":null,"time":"盘前","dateTimestamp":1787198400000,"actualEps":null},{"market":"US","date":"2026-04-07","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1775534400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"NBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.1,"name":null,"time":"盘前","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"pre","actualEps":-0.07},{"market":"US","date":"2025-05-15","symbol":"NBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.07,"name":null,"time":"盘前","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.04},{"market":"US","date":"2025-04-03","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1743652800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1759550400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBP","date":"2026-08-21","current":-4.140787,"percent":1,"low":-20.276437,"twenty":-14.583269,"median":-11.035987,"eighty":-2.356433,"high":-1.87904,"avg":-8.685292,"sd":6.054305,"marketCap":220888642},"quantilePoints":[{"date":"2025-10-31","current":-13.114792,"twenty":-13.114792,"median":-13.114792,"eighty":-13.114792,"marketCap":524460541},{"date":"2025-11-07","current":-12.077138,"twenty":-13.547148,"median":-12.71126,"eighty":-12.278904,"marketCap":482964762},{"date":"2025-11-14","current":-12.019491,"twenty":-13.114792,"median":-12.278904,"eighty":-12.077138,"marketCap":480659441},{"date":"2025-11-21","current":-12.077138,"twenty":-13.085968,"median":-12.293316,"eighty":-12.077138,"marketCap":482964762},{"date":"2025-11-28","current":-11.068308,"twenty":-13.06291,"median":-12.192433,"eighty":-11.881137,"marketCap":442621643},{"date":"2025-12-05","current":-11.500664,"twenty":-12.688201,"median":-12.077138,"eighty":-11.212426,"marketCap":459911551},{"date":"2025-12-12","current":-11.298898,"twenty":-12.411494,"median":-12.033903,"eighty":-11.287368,"marketCap":451842927},{"date":"2025-12-19","current":-17.342266,"twenty":-12.688201,"median":-12.048315,"eighty":-11.460311,"marketCap":456552482},{"date":"2025-12-26","current":-20.276437,"twenty":-13.287734,"median":-12.077138,"eighty":-11.500664,"marketCap":533797473},{"date":"2026-01-02","current":-17.429853,"twenty":-17.342266,"median":-12.163609,"eighty":-11.512194,"marketCap":458858303},{"date":"2026-01-09","current":-16.597774,"twenty":-17.482405,"median":-12.235668,"eighty":-11.541017,"marketCap":436953007},{"date":"2026-01-16","current":-16.028458,"twenty":-17.394818,"median":-12.365376,"eighty":-11.569841,"marketCap":421965173},{"date":"2026-01-23","current":-17.03571,"twenty":-17.342266,"median":-13.057145,"eighty":-11.587135,"marketCap":448482110},{"date":"2026-01-30","current":-16.116045,"twenty":-17.3773,"median":-13.33097,"eighty":-11.615959,"marketCap":424270994},{"date":"2026-02-06","current":-14.583269,"twenty":-17.342266,"median":-14.495682,"eighty":-11.742783,"marketCap":383919133},{"date":"2026-02-13","current":-14.189126,"twenty":-17.307231,"median":-14.71465,"eighty":-11.823489,"marketCap":373542940},{"date":"2026-02-20","current":-14.539475,"twenty":-17.167091,"median":-14.517578,"eighty":-11.961843,"marketCap":382766222},{"date":"2026-02-27","current":-14.364301,"twenty":-17.03571,"median":-14.408094,"eighty":-12.019491,"marketCap":378154581},{"date":"2026-03-06","current":-15.94087,"twenty":-17.03571,"median":-14.386197,"eighty":-12.048315,"marketCap":419659352},{"date":"2026-03-13","current":-12.875318,"twenty":-16.991917,"median":-14.364301,"eighty":-12.077138,"marketCap":338955631},{"date":"2026-03-20","current":-11.780478,"twenty":-16.948123,"median":-14.316021,"eighty":-12.077138,"marketCap":310132873},{"date":"2026-03-27","current":-11.167368,"twenty":-16.597774,"median":-14.189126,"eighty":-11.788901,"marketCap":293992129},{"date":"2026-04-02","current":-10.773226,"twenty":-16.597774,"median":-14.101539,"eighty":-11.587135,"marketCap":283615936},{"date":"2026-04-10","current":-3.171352,"twenty":-16.387565,"median":-14.057746,"eighty":-11.527134,"marketCap":280157205},{"date":"2026-04-17","current":-3.495376,"twenty":-16.299978,"median":-13.61981,"eighty":-11.287368,"marketCap":308781505},{"date":"2026-04-24","current":-3.23355,"twenty":-16.221149,"median":-13.10038,"eighty":-11.118286,"marketCap":285651804},{"date":"2026-05-01","current":-3.23355,"twenty":-16.203632,"median":-12.875318,"eighty":-11.061844,"marketCap":285651804},{"date":"2026-05-08","current":-2.906268,"twenty":-16.133562,"median":-12.604261,"eighty":-10.634902,"marketCap":256739678},{"date":"2026-05-15","current":-2.513529,"twenty":-16.045975,"median":-12.365376,"eighty":-3.526795,"marketCap":222045127},{"date":"2026-05-22","current":-2.330251,"twenty":-15.993423,"median":-12.293316,"eighty":-3.374936,"marketCap":205854337},{"date":"2026-05-29","current":-2.448072,"twenty":-15.958388,"median":-12.192433,"eighty":-3.235384,"marketCap":216262702},{"date":"2026-06-05","current":-2.356433,"twenty":-15.651833,"median":-12.134786,"eighty":-3.190946,"marketCap":208167307},{"date":"2026-06-12","current":-1.92442,"twenty":-15.393451,"median":-12.062727,"eighty":-3.136675,"marketCap":170003300},{"date":"2026-06-18","current":-2.055333,"twenty":-15.340898,"median":-11.990667,"eighty":-3.100019,"marketCap":181568151},{"date":"2026-06-26","current":-2.094607,"twenty":-15.292725,"median":-11.780478,"eighty":-2.890558,"marketCap":185037606},{"date":"2026-07-02","current":-2.605168,"twenty":-15.231414,"median":-11.587135,"eighty":-2.686334,"marketCap":230140522},{"date":"2026-07-10","current":-2.434981,"twenty":-15.178862,"median":-11.559911,"eighty":-2.610404,"marketCap":215106217},{"date":"2026-07-17","current":-2.343342,"twenty":-15.091275,"median":-11.517717,"eighty":-2.516147,"marketCap":207010822},{"date":"2026-07-24","current":-2.317159,"twenty":-15.012446,"median":-11.399781,"eighty":-2.437599,"marketCap":204697852},{"date":"2026-07-31","current":-2.146972,"twenty":-14.977411,"median":-11.226206,"eighty":-2.42189,"marketCap":189663546},{"date":"2026-08-07","current":-2.22552,"twenty":-14.977411,"median":-11.123574,"eighty":-2.356433,"marketCap":196602456},{"date":"2026-08-14","current":-2.487346,"twenty":-14.84603,"median":-11.068308,"eighty":-2.356433,"marketCap":219732157},{"date":"2026-08-21","current":-1.87904,"twenty":-14.583269,"median":-11.035987,"eighty":-2.356433,"marketCap":220888642}],"updateTime":1787513959247},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660284309","title":"新桥生物公布2026年上半年财务业绩，展示管线进展与战略执行亮点","url":"https://stock-news.laohu8.com/highlight/detail?id=2660284309","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660284309?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 19:11","pubTimestamp":1787224260,"startTime":"0","endTime":"0","summary":"2026年上半年，公司持续推进战略重点事项，推动核心管线取得关键临床进展，并强化了领导力、治理能力与资本配置。\" 新桥生物董事会主席傅唯表示。管线概览及近期潜在里程碑 新桥生物两大核心管线体现了公司战略核心的互补能力。2026年上半年财务业绩 现金状况 截至2026年6月30日，公司现金、现金等价物、短期投资及以公允价值计价的股权投资为2.159亿美元。研发费用 截至2026年6月30日止的六个月，研究与开发","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5030485_ZH30485_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5030485_ZH30485_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165817918","title":"新桥生物发布2026年上半年财务业绩，彰显管线动能与战略执行力","url":"https://stock-news.laohu8.com/highlight/detail?id=1165817918","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165817918?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 19:01","pubTimestamp":1787223693,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）今日披露了截至2026年6月30日的上半年财务报告，同时对外强调了其研发管线的持续推进态势，以及公司在战略层面所展现出的高效执行力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110507548","title":"新桥生物将于2026年8月20日（周四）披露2026年上半年财务业绩并发布公司最新动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1110507548","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110507548?lang=zh_cn&edition=fundamental","pubTime":"2026-08-14 05:01","pubTimestamp":1786654869,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）计划于2026年8月20日（星期四）公布其2026年上半年财务报告，届时也将同步更新公司业务进展与战略部署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530512","title":"新桥生物任命Srishti Gupta博士为首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530512","media":"美通社","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647530512?lang=zh_cn&edition=fundamental","pubTime":"2026-06-29 20:08","pubTimestamp":1782734880,"startTime":"0","endTime":"0","summary":"新桥生物董事会主席傅唯表示， \"Srishti兼具医生和首席执行官的双重视角，使她成为领导新桥生物的绝佳人选。\" 新桥生物首席执行官Srishti Gupta博士表示，\"前沿科学的创新速度，已超越行业将其传化为患者可及疗法的能力，而新桥生物正是为了弥合这一差距而创立。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4994052_ZH94052_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4994052_ZH94052_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643766548","title":"BUZZ——美国股市动态-安科科技、Dynatrace、Corvex","url":"https://stock-news.laohu8.com/highlight/detail?id=2643766548","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643766548?lang=zh_cn&edition=fundamental","pubTime":"2026-06-16 23:39","pubTimestamp":1781624358,"startTime":"0","endTime":"0","summary":".N美国东部时间11:30，道琼斯工业平均指数 .DJI 上涨0.74%，报52,052.39点。标普500指数 .SPX 下跌0.21%，报7,538.57点；纳斯达克综合指数 .IXIC 下跌0.42%，报26,571.37点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL4S42O1KM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGE","MOGU","BAC","PLAY","MBOT","QCOM","SUGP","HUBB","AMKR","HSPT","QCMU","HUN","SPAL","XOM","OTLK","OLN","LUV","MRNA","COHR","HOOD","WBX","NEO","YUM","EWTX","LITE","DT","HOOG","LION","RCL","MBLY","CCL","BAND","ALVO","GDC","SPCX","XOMO","HIMS","AMPH","CIIT","MAC","NBP","ROBN","GIL","NCLH","MOVE","CCL.UK","WDC","LITX","INTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643635257","title":"新桥生物Givastomig获美国FDA快速通道认定，用于HER2阴性转移性胃癌一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2643635257","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643635257?lang=zh_cn&edition=fundamental","pubTime":"2026-06-16 21:12","pubTimestamp":1781615520,"startTime":"0","endTime":"0","summary":"FDA快速通道认定，旨在加速针对存在未被满足医疗需求的严重疾病疗法的研发与审评。新桥生物首席医学官Phillip Dennis博士表示，\"获得快速通道认定，对Givastomig以及一线HER2阴性转移性胃癌患者而言，是意义重大的一步。Ib期结果显示，Givastomig联合免疫化疗具有稳健的疗效和良好的总体耐受性。Givastomig 目前处于开发阶段，有望用于治疗胃癌及其他CLDN18.2阳性的胃肠道恶性肿瘤。Givastomig 由新桥生物与ABL Bio公司通过一项全球合作共同开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4984809_ZH84809_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4984809_ZH84809_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["NBP","BK4585","BK4139","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643710751","title":"市场快讯——美股行情动态-高通、Robinhood、Mobileye","url":"https://stock-news.laohu8.com/highlight/detail?id=2643710751","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643710751?lang=zh_cn&edition=fundamental","pubTime":"2026-06-16 19:34","pubTimestamp":1781609681,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL4T42O0ZU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","IE00BGHQDM52.EUR","BK4604","LU1066051811.HKD","LU1244550221.USD","BK4585","BK4575","NBP","LU2065170008.USD","LU0054578231.USD","BK4231","LU2065169927.USD","ALVO","LU1974910355.USD","LU0079474960.USD","SG9999002224.SGD","LU2065171402.SGD","HOYY","BK4554","SG9999015945.SGD","QCMD","LU0942090050.USD","BK4141","LU0868494617.USD","BK4532","LU2023250504.SGD","LU0061475181.USD","HIMZ","SG9999001424.SGD","BK4515","ROBN","BK4124","SG9999002232.USD","HODU","IE00BVYPNP33.GBP","SG9999015978.USD","LU1496350502.SGD","IE00BVYPNQ40.USD","HOOX","LU2106854487.HKD","BK4539","BK4598","BK4579","LU1861559042.SGD","QCML","HOOY","LU1261432733.SGD","HOOG","MBLY","LU1823568750.SGD","HIYY","HIMS","IE00BSNM7G36.USD","HOII","QCMU","LU1069344957.HKD","BK4588","HOOW","LU1244550494.USD","HOOI","BK4080","LU2247934214.USD","LU1066051498.USD","LU1084165304.USD","LU1244550577.SGD","MAC","LU0868494708.USD","BK4534","BK4605","QCOM","BK4547","LU1066051225.USD","LU1035775433.USD","BK4573","BK4127","LU0081259029.USD","BK4196","BK4581","LU1917777945.USD","HUN","HIMY","HMYY","BK4098","LU1066053197.SGD","BK4551","LU1046421795.USD","BK4527","LU2065171311.SGD","HOOZ","GB00BDT5M118.USD","LU1861558580.USD","SG9999015952.SGD","HOOD","BK4139","BK4157","LU1119994496.HKD","BK4512","BK4612","SG9999015986.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643585751","title":"热门话题-NovaBridge股价上涨，因其胃癌联合用药获FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2643585751","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643585751?lang=zh_cn&edition=fundamental","pubTime":"2026-06-16 19:17","pubTimestamp":1781608657,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL4T42O0YR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199400680","title":"新桥生物旗下Givastomig的注册性三期临床试验最早有望于2026年第四季度启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1199400680","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199400680?lang=zh_cn&edition=fundamental","pubTime":"2026-06-16 19:01","pubTimestamp":1781607678,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）宣布，其核心候选药物Givastomig的注册性三期临床试验，预计最早将于2026年第四季度开始。这一关键性试验的启动，标志着该药物在特定适应症研发进程中迈入决定性阶段，为后续的监管申报和潜在商业化铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148595922","title":"新桥生物Givastomig获FDA快速通道资格，用于一线治疗HER2阴性转移性胃癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1148595922","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148595922?lang=zh_cn&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607647,"startTime":"0","endTime":"0","summary":"新桥生物宣布，其研发的Givastomig已获得美国食品药品监督管理局（FDA）授予的快速通道资格，该资格针对的适应症为一线治疗HER2阴性转移性胃癌。此项认定有望加速该药物的研发与审评进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164386189","title":"新桥生物：预计最早于2026年第四季度启动注册性三期联合试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1164386189","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164386189?lang=zh_cn&edition=fundamental","pubTime":"2026-03-16 20:42","pubTimestamp":1773664949,"startTime":"0","endTime":"0","summary":"新桥生物宣布，公司计划最早在2026年第四季度开展一项注册性三期联合临床试验。这一关键进展标志着其在创新疗法开发道路上迈出重要一步，为后续商业化布局奠定基础。通过将不同治疗机制相结合，该试验旨在探索更优临床效果，为患者提供突破性治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120501405","title":"新桥生物：FDA确认Givastomig有望符合加速审批资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1120501405","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120501405?lang=zh_cn&edition=fundamental","pubTime":"2026-03-16 20:39","pubTimestamp":1773664740,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式确认，新桥生物（NovaBridge Biosciences）旗下在研药物Givastomig具备潜在资格，有望通过加速审批通道推进上市进程。\n这一进展意味着，若后续临床试验数据积极，Givastomig或可基于替代终点提前获批，从而缩短其进入市场的时间。加速审批路径通常适用于针对严重疾病、且现有治疗选择有限的创新疗法。\n新桥生物表示，将继续与FDA保持密切沟通，积极推进Givastomig的临床开发计划，以期早日为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139570168","title":"新桥生物计划于2026年第四季度启动以客观缓解率为主要终点的注册性三期联合试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1139570168","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139570168?lang=zh_cn&edition=fundamental","pubTime":"2026-03-16 19:03","pubTimestamp":1773658990,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）宣布，公司将于2026年第四季度正式启动一项注册性三期联合疗法临床试验。该试验将采用客观缓解率（ORR）作为主要疗效终点，旨在评估创新疗法组合在目标患者群体中的治疗效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106527073","title":"新桥生物宣布与FDA就胃腺癌药物Givastomig加速审批路径达成建设性B类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1106527073","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106527073?lang=zh_cn&edition=fundamental","pubTime":"2026-03-16 19:02","pubTimestamp":1773658924,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）近日披露，该公司与美国食品药品监督管理局（FDA）针对其在研药物Givastomig用于治疗胃腺癌的加速批准路径，成功举行了一场富有成效的B类会议。\n此次会议重点探讨了Givastomig通过加速审批通道上市的可能性，双方就后续临床开发策略及数据要求达成重要共识。该进展标志着Givastomig在胃腺癌治疗领域的商业化进程迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618621524","title":"BUZZ--美国股票走势-Hims & Hers、Live Nation、NovaBridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621524","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618621524?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 21:30","pubTimestamp":1773063020,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4S3ZX1CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0433182093.SGD","XOMX","AGH","CAT","HIYY","FCEL","COHX","HL","RLMD","HIMY","VRTL","VRT","DTIL","SATG","LU0170899867.USD","HMYY","ITT","LYV","LUV","NEMG","AALG","COP","AAL","DAL","XENE","LU2462611646.USD","NWMX","SATS","AU","NEM","CDE","HIMS","IE00B2Q91V27.USD","PLD","NBP","UAL","SLB","XOMO","BARC.UK","HIMZ","LU1894683264.USD","LU0162691827.USD","PFE","XOMZ","RAPP","LITX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618628305","title":"BUZZ-NovaBridge 股价上涨，因眼病药物中期试验显现前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628305","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618628305?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 19:17","pubTimestamp":1773055079,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4T3ZX11X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184660068","title":"新桥生物公布二期a阶段顶线数据：Vis-101为湿性年龄相关性黄斑变性提供快速、强劲且持久的治疗反应","url":"https://stock-news.laohu8.com/highlight/detail?id=1184660068","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184660068?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 19:02","pubTimestamp":1773054152,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）最新发布的二期a阶段临床试验顶线数据显示，其核心候选药物Vis-101在治疗湿性年龄相关性黄斑变性（wet AMD）方面展现出卓越疗效。研究结果表明，该疗法能诱导快速起效、强劲且持久的治疗反应，为患者提供了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179612326","title":"新桥生物Vis-101试验结果亮眼：平均BCVA改善超10个ETDRS字母，中位CST降低100-150微米","url":"https://stock-news.laohu8.com/highlight/detail?id=1179612326","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179612326?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 19:02","pubTimestamp":1773054140,"startTime":"0","endTime":"0","summary":"新桥生物近日公布了其候选药物Vis-101的临床试验数据，结果显示其在治疗相关眼部疾病方面取得了显著成效。\n数据显示，接受Vis-101治疗的患者群体，其最佳矫正视力出现了具有临床意义的提升，平均改善幅度超过了10个ETDRS字母。与此同时，患者的中位中心凹厚度也呈现出显著下降，降低范围在100至150微米之间。\n这些积极的数据指标，为Vis-101后续的临床开发路径提供了有力的支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616551655","title":"中东欧市场：波兰央行下调基准利率后，兹罗提保持涨势","url":"https://stock-news.laohu8.com/highlight/detail?id=2616551655","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616551655?lang=zh_cn&edition=fundamental","pubTime":"2026-03-04 23:14","pubTimestamp":1772637240,"startTime":"0","endTime":"0","summary":"波兰央行周三如期下调基准利率，波兰兹罗提维持涨势。此前，随着以色列与美国袭击伊朗后冲突升级，市场对此次降息的预期愈发存疑。　　波兰央行周三将主要利率下调 25 个基点至 3.75%。波兰央行行长定于周四召开新闻发布会。　　捷克央行副行长扬弗赖特周三发表评论称，伊朗袭击事件的后续影响可能限制捷克降息空间。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-04/doc-inhpvyee3702700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["UTRE","MEURmain","EUO","FXE","EURmain","FRA","ZBmain","USVN","TNmain","ZNmain","ZFmain","UTHY","UFIV","ZTmain","NBP","BK4139","UTWY","UBmain"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}